Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illness.
Despite not undertaking clinical trials, nasal treatment R327 was accessible to the individual via Category A of the Therapeutic Goods Administration special access scheme. Recce (ASX:RCE) intends to proceed with clinical trials for the product.
The news has shot Recce’s shares up 5.1 per cent to $1.03
Copyright 2021 – Finance News Network
02 Aug 2023 - A snapshot of the stocks on the move, featuring Tamboran Resources (ASX:TBN), Sayona Mining (ASX:SYA), BCAL Diagnostics (ASX:BDX) and Nova Eye Medical (ASX:EYE).
26 Feb 2020 - Non-bank mortgage lender Resimac Group Ltd (ASX:RMC) today announced a normalised net profit of $26.9 million for the 6 months to 31 December 2019, up 85 per cent on the previous corresponding period (pcp).
02 Sep 2020 - Cardinal Resources (ASX:CDV) notes that Nordgold have increased the Offer Price in respect of their takeover bid from $0.66 to $0.90 cash per share.
18 Nov 2020 - Primewest Group Limited (ASX:PWG) reports that its wholly owned subsidiary, the manager of Vitalharvest Freehold Trust (ASX:VTH) has entered into a Facilitation Deed with Macquarie Agricultural Funds Management in support of the Macquarie Infrastructure and Real Assets (“MIRA”) proposal.
22 Jun 2022 - A snapshot of the stocks on the move, featuring Bowen Coking Coal (ASX:BCB), Coronado Global Resources (ASX:CRN), New Hope Corporation (ASX:NHC) and TerraCom (ASX:TER).
